Please login to the form below

Not currently logged in

AB Science claims first with motor neurone disease therapy

ALS patients on masitnib lived longer without their disease progressing


French biotech AB Science is celebrating after a pivotal trial of its lead drug masitinib for motor neurone disease hit its objectives.

The phase II/III study showed that masitinib was able to slow down the progression of symptoms in patients with amyotrophic lateral sclerosis (ALS), a form of MND which leads to muscle-weakness and wasting and shortened lifespan and affects around 50,000 people in Europe. Almost 80% of

ALS patients die within 5 years and 90% die within 10 years.

Two doses of masitinib (3 or 4.5mg/kg) or placebo were given on top of the only approved therapy for ALS – riluzole – and the effects of the regimens were measured against a standard rating scale of ALS symptom progression.

Not only was AB Science's drug more effective than placebo in reducing progression over a 48-week follow-up period, but patients on masitinib also lived longer without their disease progressing. Riluzole has been shown to confer a modest survival benefit, but does not have much impact on muscle strength or neurological function.

"This is very good news for the patients," said AB Science's chief executive Alain Moussy. "These final data confirm findings from the study's interim analysis and proves that masitinib is capable of slowing down motoneuron degenerative disease such as ALS, which is a devastating condition with an urgent unmet medical need."

AB Science said in a statement that this was the first time that a tyrosine kinase inhibitor such as masitinib has been shown to be effective in ALS in an advanced-stage controlled trial. The drug has a novel mechanism of action, targeting mast cells and microglia and reducing inflammation and the release of cytotoxic substances thought to contribute to the neurodegenerative process in ALS.

It is already sold as a veterinary medicine to treat mast cell tumours in dogs, but AB Science has been trying without success so far to get approval for its use in humans.

The company filed it for approval in Europe for another indication called severe indolent systemic mastocytosis last September, but was rejected by the EMA for advanced inoperable pancreatic cancer in 2014 and also turned it down for gastrointestinal stromal tumours (GIST) a year earlier. The EMA took issue with aspects of the trial design, as well as the safety of the drug and its manufacturing process.

Masitinib is also in phase III testing for Alzheimer's disease, multiple sclerosis, asthma, rheumatoid arthritis, and for various cancers. It has been granted orphan status for ALS from both the EMA and FDA.

Article by
Phil Taylor

22nd March 2017

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...